ABC.L Regulatory News (ABC)

ABCAM PLC

("Abcam" or "the Company")

Notification of Interim Results

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that its Interim Report for the six months ended 31 December 2011 has been posted to shareholders and is available at the Company's investor relations website, www.abcamplc.com.

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.

Abcam now has an online catalogue of over 88,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.